Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: genetics – Page 283

Envisioning an animal-free drug supply, scientists have — for the first time — reprogrammed a common bacterium to make a designer polysaccharide molecule used in pharmaceuticals and nutraceuticals. Published on March 22021, in Nature Communications, the researchers modified E. coli to produce chondroitin sulfate, a drug best known as a dietary supplement to treat arthritis that is currently sourced from cow trachea.

Genetically engineered E. coli is used to make a long list of medicinal proteins, but it took years to coax the bacteria into producing even the simplest in this class of linked sugar molecules — called sulfated glycosaminoglycans — that are often used as drugs and nutraceuticals…

“It’s a challenge to engineer E. coli to produce these molecules, and we had to make many changes and balance those changes so that the bacteria will grow well,” said Mattheos Koffas, lead researcher and a professor of chemical and biological engineering at Rensselaer Polytechnic Institute. “But this work shows that it is possible to produce these polysaccharides using E. coli in animal-free fashion, and the procedure can be extended to produce other sulfated glycosaminoglycans.”

Read more | >

While these tools will enable our society to reopen (and stay open) by improving detection of the virus, CRISPR will also have an important effect on the way we treat other diseases. In 2021, we will see increased use of CRISPR-Cas enzymes to underpin a new generation of cost-effective, individualised therapies. With CRISPR enzymes, we can cut DNA at precise locations, using specifically designed proteins, and insert or delete pieces of DNA to correct mutations.

As we deepen our understanding of the human genome and genetic disorders, patients with previously intractable diseases, such as sickle-cell disease and cancer, will benefit more widely from CRISPR-based therapies that are rapidly moving from the lab to the clinic. In 2019, sickle-cell patient Victoria Gray, for example, became one of the first patients in the world to receive CRISPR therapy for her genetic disease. She has already seen significant improvements to her health, including reduced pain and less frequent need for blood transfusions.

CRISPR will also allow us to act more boldly in the face of other important, interconnected issues such as food security, environmental sustainability and social inequality. The technology will help us grow more nutritious and robust crops, establish “gene drives” to control the spread of other infectious diseases such as Zika, and develop cleaner energy sources such as algae-based biofuels.

Read more | >

Researchers affiliated with Nvidia and Harvard today detailed AtacWorks, a machine learning toolkit designed to bring down the cost and time needed for rare and single-cell experiments. In a study published in the journal Nature Communications, the coauthors showed that AtacWorks can run analyses on a whole genome in just half an hour compared with the multiple hours traditional methods take.

Most cells in the body carry around a complete copy of a person’s DNA, with billions of base pairs crammed into the nucleus. But an individual cell pulls out only the subsection of genetic components that it needs to function, with cell types like liver, blood, or skin cells using different genes. The regions of DNA that determine a cell’s function are easily accessible, more or less, while the rest are shielded around proteins.

AtacWorks, which is available from Nvidia’s NGC hub of GPU-optimized software, works with ATAC-seq, a method for finding open areas in the genome in cells pioneered by Harvard professor Jason Buenrostro, one of the paper’s coauthors. ATAC-seq measures the intensity of a signal at every spot on the genome. Peaks in the signal correspond to regions with DNA such that the fewer cells available, the noisier the data appears, making it difficult to identify which areas of the DNA are accessible.

Read more | >

SB Acharyya.

This is correct https://www.frontiersin.org/…/10…/fnhum.2010.00224/

Sesame seed-size brains created from a mix of human and Neanderthal genes lived briefly in petri dishes in a University of California, San Diego laboratory, offering tantalizing clues as to how the organs have evolved over millennia.

Scientists have long wondered how human beings evolved to have such big, complex brains. One way to figure that out is by comparing modern genes involved in brain development with those found in our ancient cousins. Though scientists have found plenty of fossilized remains from Neanderthals — cousins of modern humans that died out about 37000 years ago — they have yet to find a preserved Neanderthal brain. To bridge that gap in knowledge, a research team grew tiny, unconscious “minibrains” in petri dishes. Some of the brains were grown using standard human genes, and others were altered using the gene-editing tool CRISPR to have a brain development gene taken from Neanderthal remains.

Continue reading “Scientists grow human-Neanderthal hybrid ‘minibrains’ in petri dishes” | >

Integrated circuits, brain sciences, genetics and biotechnology, clinical medicine and health care, and deep Earth, sea, space and polar exploration were named as the other five sectors that will be given priority in terms of funding and resources, according to a draft of the government’s 14th five-year plan for 2021–25, and its vision through 2035.

‘Basic research is the wellspring of scientific and technological innovation, so we’ll boost spending in this area by a considerable sum,’ Premier Li Keqiang says.

Read more | >

Crown Bioscience (CrownBio), JSR Life Sciences and Cambridge Quantum Computing (CQC) today announced a partnership agreement to explore the application of quantum technology to drive the identification of multi-gene biomarker discovery for oncology drug discovery.

Read more | >

Dr. John Torday, Ph.D. is an Investigator at The Lundquist Institute of Biomedical Innovation, a Professor of Pediatrics and Obstetrics/Gynecology, and Faculty, Evolutionary Medicine, at the David Geffen School of Medicine at UCLA, and Director of the Perinatal Research Training Program, the Guenther Laboratory for Cell-Molecular Biology, and Faculty in the Division of Neonatology, at Harbor-UCLA Medical Center.

Dr. Torday studies the cellular-molecular development of the lung and other visceral organs, and using the well-established principles of cell-cell communication as the basis for determining the patterns of physiologic development, his laboratory was the first to determine the complete repertoire of lung alveolar morphogenesis. This highly regulated structure offered the opportunity to trace the evolution of the lung from its unicellular origins forward, developmentally and phylogenetically. The lung is an algorithm for understanding the evolution of other physiologic properties, such as in the kidney, skin, liver, gut, and central nervous system. Such basic knowledge of the how and why of physiologic evolution is useful in the effective diagnosis and treatment of disease.

Dr. Torday received his undergraduate degree in Biology and English from Boston University, and his MSc and PhD in Experimental Medicine from McGill University, Montreal, Canada. He did a post-doctoral Fellowship in Reproductive Endocrinology at the University of Wisconsin-Madison, WI.

Dr. Torday’s research has led to the publication of more than 150 peer-reviewed articles and 350 abstracts. More recently, he has gained an interest in the evolutionary aspects of comparative physiology and development, leading to the publication of 12 peer-reviewed articles on the cellular origins of vertebrate physiology, culminating in the book Evolutionary Biology, Cell-Cell Communication and Complex Disease.

Continue reading “Dr. John S Torday — Lundquist Institute / UCLA — Aging And Disease As A Process Of Reverse Evolution” | >

Some genes don’t stay in the same place in the genome. Sometimes called jumping genes or transposons, this genetic material can hop around and rearrange itself | Genetics And Genomics.

Some genetic sequences don’t stay in the same place in the genome. Sometimes called jumping genes or transposons, this genetic material can hop around and rearrange itself to create new sequences. Some transposons even encode for their own enzymes, and these co-called transposases can edit the genome by cutting sequences from one place and pasting them to another.

Reporting in Science, researchers have now suggested that transposable elements (TEs) can fuse with portions of existing genes that code for protein called exons, and get incorporated into genes in a process called exon shuffling to create novel genes that are functional, and express new proteins.

Continue reading “New Genes Can Form From ‘Jumping Gene Fusions” | >

This is a detailed summary of plasma dilution and at 58:38 the future is explained where they will publish human results from 25 people, then start a company whose first order of business will be phase 3 trials with more people and placebo and hopefully funding. It appears you can pay to have the procedure. The hopeful start is this year in may.

Irina will present her recent findings on plasma dilution, showing that age-reversing effects, such as rejuvenating tissues in mice, can be achieved by.
diluting the blood plasma of old mice: Rejuvenation of three germ layers tissues by exchanging old blood plasma with saline-albumin.

Irina’s research focus.

Continue reading “Tissue Rejuvenation via Plasma Dilution | Irina Conboy, UC Berkeley” | >